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Medium and long-term risks of specific cardiovascular 
diseases in survivors of 20 adult cancers: a population-based 
cohort study using multiple linked UK electronic health 
records databases
Helen Strongman, Sarah Gadd, Anthony Matthews, Kathryn E Mansfield, Susannah Stanway, Alexander R Lyon, Isabel dos-Santos-Silva, 
Liam Smeeth, Krishnan Bhaskaran
Summary
Background The past few decades have seen substantial improvements in cancer survival, but concerns exist about 
long-term cardiovascular disease risk in survivors. Evidence is scarce on the risks of specific cardiovascular diseases 
in survivors of a wide range of cancers to inform prevention and management. In this study, we used large-scale 
electronic health records data from multiple linked UK databases to address these evidence gaps.
Methods For this population-based cohort study, we used linked primary care, hospital, and cancer registry data from 
the UK Clinical Practice Research Datalink to identify cohorts of survivors of the 20 most common cancers who were 
18 years or older and alive 12 months after diagnosis and controls without history of cancer, matched for age, sex, and 
general practice. We compared risks for a range of cardiovascular disease outcomes using crude and adjusted Cox 
models. We fitted interactions to investigate effect modification, and flexible parametric survival models to estimate 
absolute excess risks over time.
Findings Between Jan 1, 1990, and Dec 31, 2015, 126 120 individuals with a diagnosis of a cancer of interest still being 
followed up at least 1 year later were identified and matched to 630 144 controls. After exclusions, 108 215 cancer 
survivors and 523 541 controls were included in the main analyses. Venous thromboembolism risk was elevated in 
survivors of 18 of 20 site-specific cancers compared with that of controls; adjusted hazard ratios (HRs) ranged from 
1·72 (95% CI 1·57–1·89) in patients after prostate cancer to 9·72 (5·50–17·18) after pancreatic cancer. HRs decreased 
over time, but remained elevated more than 5 years after diagnosis. We observed increased risks of heart failure or 
cardiomyopathy in patients after ten of 20 cancers, including haematological (adjusted HR 1·94, 1·66–2·25, with 
non-Hodgkin lymphoma; 1·77, 1·50–2·09, with leukaemia; and 3·29, 2·59–4·18, with multiple myeloma), 
oesophageal (1·96, 1·46–2·64), lung (1·82, 1·52–2·17) kidney (1·73, 1·38–2·17) and ovarian (1·59, 1·19–2·12). 
Elevated risks of arrhythmia, pericarditis, coronary artery disease, stroke, and valvular heart disease were also observed 
for multiple cancers, including haematological malignancies. HRs for heart failure or cardiomyopathy and venous 
thromboembolism were greater in patients without previous cardiovascular disease and in younger patients. However, 
absolute excess risks were generally greater with increasing age. Increased risks of these outcomes seemed most 
pronounced in patients who had received chemotherapy.
Interpretation Survivors of most site-specific cancers had increased medium-term to long-term risk for one or more 
cardiovascular diseases compared with that for the general population, with substantial variations between cancer sites.
Funding Wellcome Trust and Royal Society.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Improvements in cancer survival in the past few decades 
have resulted in a large and growing population of long-
term cancer survivors; about half of patients diagnosed 
with cancer in high-income settings are now expected to 
survive for 10 years or longer.1 However, significant 
concerns exist that there might be increased medium-
term to long-term risks of cardiovascular diseases after 
cancer diagnosis, driven by cardiotoxic treatment effects, 
mechanisms directly related to cancer biology, and 
shared risk factors.2–8
Although randomised trials have shown short-term to 
medium-term adverse cardiovascular effects of some 
specific cancer treatments, such studies cannot quantify 
the broader differences in risk between cancer survivors 
and individuals with no history of cancer.2 Several 
observational studies9 comparing survivors of adolescent 
and young adult-onset cancer with age-matched controls 
with no history of cancer or controls from a general 
population found substantially increased risks of cardio-
vascular disease during the time after survival. However, 
results varied by age, suggesting that estimates from 
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these studies might not generalise to adult-onset cancer 
survivors. Long-term follow-up after cancer is increasingly 
available through linked electronic health record 
databases. To date, most studies in adults have focused on 
a composite cardiovascular disease outcome, suggesting 
that people with a history of some, but not all, cancers are 
at increased risk of cardiovascular disease.10 However, 
evidence exists of heterogeneous associations between 
different cancers and different cardiovascular disease 
outcomes.11 Few individual studies have examined risks of 
multiple specific outcomes of cardiovascular disease 
in survivors of a wide range of site-specific cancers 
to show the broader patterns of risk within a single 
methodologically coherent framework. Additionally, few 
studies were able to include data on key shared risk 
factors for cancer and cardiovascular disease, such as 
smoking and body-mass index (BMI), to help delineate 
the drivers of cardiovascular disease risk in cancer 
survivors.
To address these evidence gaps, we aimed to use large-
scale electronic health records data from multiple linked 
UK databases to quantify the absolute and relative risks 
of a comprehensive range of cardiovascular diseases in 
survivors of the 20 most common site-specific adult 
cancers, covering more than 90% of all cancer diagnoses,1 
compared with cancer-free controls from the general 
population. We also investigated the extent to which 
relative risk differences are driven by shared risk factors, 
demographic characteristics, and use of chemotherapy 
and radiotherapy.
Methods
Study design and participants
In this population-based cohort study, we identified 
20 matched cohorts to compare risks of cardiovascular 
disease outcomes in survivors of the 20 most common 
site-specific cancers1 with those of cancer-free controls, 
using Clinical Practice Research Datalink primary care 
data (CPRD GOLD) linked to national data on hospital 
admissions from the Hospital Episode Statistics Admitted 
Patient Care (HES APC) database, cancer registrations 
from the National Cancer Registration and Analysis 
Service (NCRAS), death registrations—including cause 
of death information—from the Office of National 
Statistics mortality database, and postcode-based index of 
Multiple Deprivation data.12,13 CPRD GOLD comprises 
prospectively collected primary care records from general 
practices in the UK that use Vision software and have 
chosen to participate; this database includes approximately 
7% of the UK population and captures coded diagnoses 
and care events (using Read coding),14 prescriptions 
issued in primary care, and numerical test results (eg, 
blood pressure readings). Secondary care diagnoses are 
typically reported back to the general practitioner (GP) 
and recorded in the primary care record if they are 
considered to affect the ongoing care of the patient. 
Research in context
Evidence before this study
We searched PubMed and OVID MEDLINE for epidemiological 
studies, reviews, and guidelines published in English from 
Jan 1, 2008, to Dec 31, 2018, using search terms for 
cardiovascular outcomes and cancer (details of search terms are 
in the appendix [pp 45–46]). We identified articles that provided 
estimates comparing risks of any of the specific cardiovascular 
disease outcomes included in our study between adult survivors 
of one or more site-specific cancers and controls without a 
history of cancer. 21 studies were included; eight focused on 
cardiovascular risks in patients after breast cancer and seven 
included multiple cancer sites, but six of these were restricted to 
teenage-onset and young adult-onset cancers (appendix 
pp 47–51). Relative risk estimates from previous studies were 
extracted and are displayed alongside estimates from our study 
in the appendix (pp 52–59). The most commonly studied 
outcomes were coronary artery disease and stroke: 95% CIs for 
most estimates crossed the null but were too wide to exclude 
modest associations. Some evidence was found of increased risks 
of both outcomes in patients after non-Hodgkin lymphoma, 
whereas stroke risk was markedly elevated for survivors of CNS 
cancer in all three relevant studies. Increased risks of heart failure 
or cardiomyopathy were observed in patients after several 
types of cancers, notably haematological malignancies. Elevated 
risks of venous thromboembolism were seen in most studies of 
this outcome, though few estimates were available per cancer 
site. Little previous evidence was available for other outcomes.
Added value of this study
Survivors of most site-specific cancers had increased risk of 
one or more cardiovascular disease outcomes, but patterns 
of risk varied by cancer site and by outcome. We found a 
substantially increased risk of venous thromboembolism 
for most cancers and increased risks of heart failure or 
cardiomyopathy in survivors of half of cancers investigated. 
Risks of other cardiovascular disease outcomes, including 
coronary artery disease and stroke, were elevated in survivors 
of several specific cancers, including haematological 
malignancies. Associations between cancer and cardiovascular 
risk did not appear to be explained by shared risk factors, 
but exploratory analyses highlighted chemotherapy as an 
important driver of risk.
Implications of all the available evidence
Our study is one of the largest to date to compare risks for a 
wide range of cardiovascular disease outcomes between adult 
survivors of multiple site-specific cancers and controls with no 
history of cancer, with a consistent methodological approach 
that allowed us to reveal detailed patterns of risk. Our findings 
show that more tailored strategies to minimise and manage 
cardiovascular risk are needed for people who survive cancer. 
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Linked HES APC and NCRAS data added information 
coded according to the International Classification of 
Diseases, version 10 (ICD-10), on hospital diagnoses and 
cancer registrations, improving capture of clinical events. 
Linked data sources covered England only between 
Jan 1, 1990, and Dec 31, 2015; therefore our primary ana-
lyses were restricted to this setting and time period.
We used CPRD GOLD, HES APC, and NCRAS to 
identify patients aged 18 years or older with an incident 
primary site-specific cancer of interest (list of cancers is 
presented in figure 1). Incident cancer was defined as 
the first code for cancer at the site of interest in any of 
the linked databases, at least 1 year after the start of 
research-quality follow-up (research-quality follow-up 
is determined by CPRD on the basis of a set of basic 
practice and patient-level data quality checks).12 Patients 
with no information on smoking, BMI, or index of 
Multiple Deprivation (an area-based proxy for socio-
economic status) were excluded from the analysis. 
Patients were also excluded if they had less than 1 year of 
follow-up after their incident cancer diagnosis.
This study was approved by the London School of 
Hygiene & Tropical Medicine Ethics Committee (12042) 
and the Independent Scientific Advisory Committee for 
the Medicines and Healthcare products Regulatory 
Agency database research (16_274). The study protocol 
is available in the appendix (pp 63–76). CPRD supplies 
anonymised data for public health research; therefore 
individual patient consent was not required for this study.13
Procedures
Cancer survivors entered the study 1 year after diagnosis 
(index date) and were matched on age (±3 years), sex, and 
general practice with up to five controls with no history 
of cancer and at least 24 months of continuous preceding 
follow-up on the index date of the matched cancer 
survivor (mirroring the requirement on cancer survivors 
to have 1 year of follow-up before and after cancer 
diagnosis to enter the study on the index date). If a 
control went on to receive an incident cancer diagnosis 
during follow-up, they were no longer available as a 
control at that time but could then contribute as a site-
specific cancer survivor (if the cancer was at one of the 
20 sites of interest) with their own set of matched controls.
The outcomes of the study were fatal or non-fatal 
coronary artery disease (angina, myocardial infarction, 
revascularisation procedures, and sudden cardiac arrest), 
stroke (haemorrhagic and ischaemic stroke), arrhythmia, 
venous thromboembolism (deep vein thrombosis and 
pulmonary embolism), heart failure and cardiomyopathy 
combined, pericarditis, valvular heart disease, and 
peripheral vascular disease. Component outcomes within 
coronary artery disease, venous thromboembolism, and 
heart failure or cardiomyopathy were also analysed 
separately. We identified outcomes using Read codes 
within CPRD GOLD, ICD-10 codes within HES APC, and 
ICD-9–10 codes within the ONS mortality database.
Demographics and shared risk factors, including 
smoking, BMI, and comorbidities, were identified at the 
cancer diagnosis date for the cancer survivor group and 
at 1 year before the index date for the matched cohort. 
Full covariate definitions are provided in the appendix 
(pp 4–6). Code lists for all study variables are available 
online.
Statistical analysis
For all analyses of each outcome, patients were followed 
up from the index date (ie, the first anniversary of 
diagnosis for the cancer survivor in each matched set) 
until the earliest occurrence of: death, end of research-
quality follow-up, end of study period, or first occurrence 
of an outcome. Patients with a record of an outcome of 
interest before the index date were excluded from the 
analysis of that outcome. We calculated crude incidences 
for each cardiovascular disease outcome in cancer 
survivors and matched controls, with separate models for 
each cancer site. To relate site-specific cancer history to 
risk of each cardiovascular disease outcome, we then 
fitted Cox proportional hazards models with time since 
index date as the timescale, initially accounting only for 
matching factors (age, sex, and general practice) through 
stratification by matched set and then additionally 
adjusting for shared risk factors and demographics listed 
in table 1. Severe mental illness, rheumatoid arthritis, and 
systemic lupus erythematosus were considered but 
were not included in the final models because they were 
rare within the study population. We made additional 
adjustments in analyses of specific cancers, namely for 
hysterectomy and previous hormone replacement therapy 
(in analyses of all female-specific cancers), chronic liver 
disease (liver cancer analysis), immunosuppression (non-
Hodgkin lymphoma analysis), and sclerosis and chronic 
obstructive pulmonary disease (lung cancer analysis). A 
directed acyclic graph in the appendix (p 7) sets out the 
postulated causal relationships between covariates and 
thus, the causal framework assumed by our models.15
We investigated the modification of the effect of cancer 
survival on cardiovascular disease risk by the following 
variables by fitting interaction terms and doing likelihood 
ratio tests for interaction: age group, sex, smoking status, 
BMI, other pre-existing cardiovascular disease at index 
date, hypertension at index, Index of Multiple Deprivation, 
and calendar period. Proportional hazards were checked 
by fitting interactions with time since index date. 
Definitions of interaction terms are provided in the 
appendix (pp 4–6). These analyses of effect modification 
were restricted to the nine most common cancers 
(colorectal, lung, malignant melanoma, breast, uterus, 
prostate, bladder, non-Hodgkin lymphoma, and leukae-
mia) and the outcomes of coronary artery disease, stroke, 
arrhythmia, heart failure or cardiomyopathy, and venous 
throm boembolism, because power was too low for other 
combinations. For the six of nine cancers for which at 
least 75% of tumours were recorded in NCRAS, we also 
See Online for appendix
For the code list see https://
datacompass.lshtm.ac.uk/1113/
Articles
4 www.thelancet.com   Published online August 20, 2019   http://dx.doi.org/10.1016/S0140-6736(19)31674-5
20·9/17·2
6·4/7·5
3·8/3·7
7·7/6·2
13·8/14·7
19·0/15·8
17·1/12·7
16·9/14·0
17·6/13·9
24·7/14·8
8·8/8·6
20·3/13·8
14·1/11·6
19·3/13·9
14·3/12·3
7·0/6·4
19·0/14·2
20·0/19·1
6·0/4·5
8·4/9·3
1·25 (1·12–1·40)
1·31 (1·17–1·46)
0·84 (0·77–0·92)
0·86 (0·79–0·93)
1·04 (0·58–1·87)
1·11 (0·68–1·81)
1·52 (0·85–2·73)
1·46 (0·85–2·49)
0·99 (0·90–1·09)
0·98 (0·90–1·08)
1·07 (0·78–1·46)
1·08 (0·80–1·46)
1·21 (0·95–1·55)
1·39 (1·10–1·75)
1·23 (1·02–1·47)
1·25 (1·04–1·49)
1·53 (0·72–3·27)
1·43 (0·77–2·66)
1·42 (1·18–1·72)
1·70 (1·43–2·03)
1·12 (0·96–1·30)
1·07 (0·92–1·23)
1·87 (1·44–2·43)
1·84 (1·43–2·36)
1·30 (1·10–1·54)
1·29 (1·10–1·52)
1·74 (1·27–2·37)
1·65 (1·22–2·22)
1·14 (0·85–1·51)
1·10 (0·84–1·45)
1·22 (0·90–1·64)
1·25 (0·94–1·67)
1·14 (0·69–1·90)
1·28 (0·81–2·03)
1·09 (1·02–1·17)
1·07 (1·00–1·14)
1·43 (0·83–2·46)
1·35 (0·83–2·20)
0·94 (0·75–1·18)
0·97 (0·79–1·19)
IR CS/GPC HR (95% CI) IR CS/GPC HR (95% CI)
[3145]
Bladder (C67)
[5793]
Breast (C50)
[151]
Cervix (C53)
[161]
CNS (C71–72)
[5023]
Colorectal (C18–20)
[548]
Stomach (C16)
[677]
Kidney (C64)
[1196]
Leukaemia (C91–95) Leukaemia (C91–95)
[148]
Liver (C22)
[1827]
Lung (C34)
[1629]
Malignant melanoma (C43)
Malignant melanoma (C43)Malignant melanoma (C43)
Malignant melanoma (C43)
[617]
 Multiple myeloma (C90)
Leukaemia (C91–95)
Multiple myeloma (C90)
Leukaemia (C91–95)
Multiple myeloma (C90)
 Multiple myeloma (C90)
[1364]
NHL (C82–85)
[564]
Oesophageal (C15)
[501]
Oral cavity (C00–06)
[532]
Ovaries (C56)
[264]
Pancreas (C25)
[8178]
Prostate (C61)
[133]
Thyroid (C73)
[890]
Uterus (C54–55)
Coronary artery disease
30·3/27·5
17·2/16·8
11·1/11·8
12·0/11·6
26·2/25·0
29·2/25·2
27·4/20·9
27·5/22·9
23·3/20·1
42·3/24·0
19·4/16·9
36·2/24·5
26·7/19·9
37·5/23·4
20·8/19·6
16·9/15·8
24·3/22·7
29·5/29·5
18·6/12·4
22·5/18·9
1·14 (1·04–1·25)
1·16 (1·06–1·26)
1·03 (0·98–1·09)
1·04 (0·98–1·10)
0·96 (0·71–1·32)
1·01 (0·75–1·36)
1·44 (0·91–2·27)
1·46 (0·95–2·25)
1·09 (1·01–1·17)
1·07 (1·00–1·15)
1·22 (0·94–1·58)
1·21 (0·94–1·57)
1·28 (1·06–1·56)
1·39 (1·16–1·68)
1·34 (1·17–1·55)
1·36 (1·18–1·57)
1·53 (0·82–2·84)
1·52 (0·86–2·68)
1·85 (1·60–2·14)
1·97 (1·71–2·26)
1·22 (1·10–1·35)
1·19 (1·07–1·32)
1·90 (1·55–2·33)
1·89 (1·55–2·30)
1·53 (1·35–1·74)
1·53 (1·36–1·74)
1·98 (1·56–2·52)
1·93 (1·53–2·43)
1·09 (0·87–1·38)
1·07 (0·85–1·33)
1·07 (0·88–1·30)
1·13 (0·93–1·36)
1·40 (0·92–2·14)
1·38 (0·92–2·08)
1·07 (1·01–1·13)
1·04 (0·99–1·10)
1·62 (1·20–2·18)
1·61 (1·20–2·15)
1·15 (0·99–1·34)
1·21 (1·05–1·39)
[5083]
Bladder (C67)
[12304]
Breast (C50)
[440]
Cervix (C53)
[283]
CNS (C71–72)
[8538]
Colorectal (C18–20)
[872]
Stomach (C16)
[1094]
Kidney (C64)
[1930]
[207]
Liver (C22)
[2976]
Lung (C34)
[3127]
[1066]
[2311]
NHL (C82–85)
[950]
Oesophageal (C15)
[780]
Oral cavity (C00–06)
[1220]
Ovaries (C56)
[404]
Pancreas (C25)
[13107]
Prostate (C61)
[343]
Thyroid (C73)
[1743]
Uterus (C54–55)
Arrhythmia
22·2/18·3
7·8/7·2
2·4/3·0
4·7/4·7
14·1/15·0
19·7/17·1
19·7/11·4
19·4/14·0
21·1/12·6
25·4/14·3
7·6/8·6
30·1/14·6
18·6/10·7
20·1/13·5
10·2/10·8
8·6/6·1
15·2/11·9
18·9/19·2
4·7/5·1
10·2/8·6
1·19 (1·07–1·31)
1·26 (1·15–1·38)
1·13 (1·05–1·23)
1·14 (1·06–1·23)
0·74 (0·36–1·51)
1·04 (0·57–1·90)
1·13 (0·53–2·40)
1·40 (0·73–2·70)
1·00 (0·91–1·09)
0·98 (0·90–1·07)
1·24 (0·93–1·66)
1·21 (0·91–1·59)
1·73 (1·38–2·17)
1·90 (1·54–2·35)
1·77 (1·50–2·09)
1·65 (1·41–1·93)
1·93 (1·01–3·71)
2·10 (1·20–3·70)
1·82 (1·52–2·17)
2·14 (1·82–2·52)
0·94 (0·81–1·10)
0·92 (0·79–1·07)
3·29 (2·59–4·18)
2·85 (2·30–3·54)
1·94 (1·66–2·25)
1·94 (1·68–2·23)
1·96 (1·46–2·64)
1·88 (1·42–2·48)
0·89 (0·66–1·22)
0·97 (0·72–1·30)
1·59 (1·19–2·12)
1·67 (1·28–2·18)
1·45 (0·86–2·45)
1·39 (0·85–2·25)
1·12 (1·05–1·20)
1·06 (1·00–1·13)
0·71 (0·41–1·23)
0·85 (0·51–1·40)
0·98 (0·79–1·21)
1·17 (0·96–1·41)
Cancer type or site (ICD-10)  [number of outcomes] Cancer type or site (ICD-10)  [number of outcomes]
[3954]
Bladder (C67)
[6128]
Breast (C50)
[122]
Cervix (C53)
[126]
CNS (C71–72)
[5807]
Colorectal (C18–20)
[677]
Stomach (C16)
[719]
Kidney (C64)
[1387]
[154]
Liver (C22)
[2053]
Lung (C34)
[1724]
[781]
[1489]
NHL (C82–85)
[630]
Oesophageal (C15)
[480]
Oral cavity (C00–06)
[558]
Ovaries (C56)
[247]
Pancreas (C25)
[9735]
Prostate (C61)
[146]
Thyroid (C73)
[925]
Uterus (C54–55)
0·5 1·0 2·0 4·0 8·0
Heart failure or cardiomyopathy
15·1/13·6
6·8/6·6
4·1/3·4
13·2/4·2
12·3/12·0
14·2/13·8
11·0/10·0
13·0/10·7
13·4/9·8
19·5/11·6
7·4/7·2
16·3/11·1
11·2/8·9
11·2/11·6
11·2/8·1
7·2/6·3
15·4/10·7
14·5/14·3
3·8/4·1
8·3/7·6
1·07 (0·95–1·19)
1·14 (1·02–1·28)
1·07 (0·99–1·16)
1·08 (1·00–1·17)
1·78 (1·01–3·17)
1·70 (1·01–2·87)
4·42 (2·54–7·72)
4·48 (2·68–7·48)
1·06 (0·97–1·17)
1·06 (0·96–1·16)
1·08 (0·78–1·49)
1·11 (0·81–1·52)
1·00 (0·77–1·30)
1·11 (0·86–1·43)
1·38 (1·14–1·67)
1·35 (1·12–1·62)
1·25 (0·59–2·64)
1·49 (0·77–2·86)
1·51 (1·26–1·82)
1·78 (1·50–2·12)
1·10 (0·94–1·28)
1·07 (0·92–1·24)
1·69 (1·28–2·23)
1·73 (1·33–2·24)
1·48 (1·24–1·76)
1·46 (1·23–1·74)
1·23 (0·85–1·79)
1·27 (0·89–1·82)
1·46 (1·07–2·00)
1·57 (1·16–2·11)
1·25 (0·94–1·66)
1·28 (0·98–1·68)
1·84 (1·09–3·12)
1·68 (1·04–2·73)
1·06 (0·99–1·14)
1·04 (0·97–1·11)
0·78 (0·42–1·42)
0·88 (0·52–1·49)
1·14 (0·92–1·42)
1·10 (0·90–1·35)
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[7353]
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[117]
Thyroid (C73)
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0·5 1·0 2·0 4·0 8·0
Stroke
Stratified by age–matched, gender–matched, and general practice-matched  sets         Additionally adjusted for shared risk factors
A
Lower risk Higher risk Lower risk Higher risk
(Figure 1 continues on next page)
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Cancer type or site (ICD-10)  [number of outcomes] Cancer type or site (ICD-10)  [number of outcomes]
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Kidney (C64)
Liver (C22)
Lung (C34)
NHL (C82–85)
Oesophageal (C15)
Oral cavity (C00–06)
Ovaries (C56)
Pancreas (C25)
Prostate (C61)
Thyroid (C73)
Uterus (C54–55)
0·5 1·0 2·0 4·0 8·0
Pericarditis
Bladder (C67)
Breast (C50)
Cervix (C53)
CNS (C71–72)
Colorectal (C18–20)
Stomach (C16)
Kidney (C64)
Liver (C22)
Lung (C34)
NHL (C82–85)
Oesophageal (C15)
Oral cavity (C00–06)
Ovaries (C56)
Pancreas (C25)
Prostate (C61)
Thyroid (C73)
Uterus (C54–55)
0·5 1·0 2·0 4·0 8·0
Valvular heart diseases
B
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7·4/5·5
2·0/2·2
1·4/1·2
0·7/1·7
4·6/4·7
5·1/5·3
6·1/4·5
6·0/4·7
9·1/4·8
7·2/4·4
2·4/2·8
4·7/4·5
4·6/4·0
4·4/5·5
5·3/4·0
1·9/2·2
5·7/3·3
5·2/6·5
1·6/1·7
3·2/2·5
1·19 (1·01–1·41)
1·34 (1·15–1·57)
0·88 (0·75–1·02)
0·91 (0·79–1·05)
··
··
··
··
1·02 (0·88–1·19)
1·01 (0·88–1·17)
0·95 (0·55–1·64)
1·08 (0·65–1·77)
0·89 (0·60–1·33)
1·39 (0·98–1·95)
1·31 (0·98–1·76)
1·29 (0·99–1·68)
··
··
1·44 (1·04–1·98)
1·93 (1·45–2·58)
0·89 (0·68–1·17)
0·86 (0·67–1·10)
0·97 (0·59–1·61)
1·05 (0·67–1·62)
1·27 (0·96–1·67)
1·22 (0·95–1·58)
1·01 (0·56–1·84)
1·13 (0·66–1·91)
1·22 (0·76–1·97)
1·35 (0·90–2·03)
0·76 (0·42–1·38)
0·87 (0·52–1·46)
2·05 (0·78–5·44)
1·42 (0·67–3·00)
0·94 (0·84–1·05)
0·86 (0·77–0·95)
··
··
1·52 (1·01–2·27)
1·52 (1·09–2·12)
9·9/5·4
7·2/3·8
7·6/2·2
11·1/2·2
11·6/5·3
12·5/6·0
13·1/4·2
9·1/5·2
22·6/4·8
22·6/5·1
5·1/3·4
15·5/5·6
8·9/4·6
13·1/5·2
6·7/4·3
16·7/3·5
29·0/4·5
9·3/5·7
2·9/2·4
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2·01 (1·73–2·32)
2·06 (1·78–2·37)
2·01 (1·85–2·19)
2·00 (1·84–2·17)
5·13 (3·14–8·37)
4·55 (2·93–7·05)
6·43 (3·21–12·90)
7·04 (3·81–13·03)
2·47 (2·22–2·75)
2·45 (2·20–2·72)
2·90 (1·93–4·36)
2·74 (1·87–4·01)
3·38 (2·48–4·59)
3·29 (2·49–4·35)
1·98 (1·57–2·51)
1·92 (1·53–2·41)
7·43 (3·19–17·28)
3·93 (2·12–7·26)
5·24 (4·21–6·51)
5·05 (4·14–6·16)
1·73 (1·42–2·09)
1·64 (1·36–1·98)
3·95 (2·80–5·56)
3·78 (2·78–5·14)
2·24 (1·81–2·77)
2·18 (1·78–2·66)
3·46 (2·22–5·38)
3·67 (2·48–5·43)
1·37 (0·93–2·01)
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1·20 (0·82–1·76)
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··
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2·34 (0·94–5·80)
2·00 (0·93–4·29)
2·55 (1·45–4·48)
2·16 (1·30–3·60)
··
··
6·27 (3·79–10·37)
6·71 (4·39–10·26)
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1·08 (0·66–1·77)
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3·64 (1·69–7·81)
2·56 (1·48–4·44)
2·45 (1·52–3·95)
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3·07 (1·34–7·03)
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1·00 (0·90–1·10)
··
··
3·01 (0·99–9·13)
2·58 (1·10–6·02)
0·93 (0·82–1·04)
0·91 (0·81–1·02)
1·22 (0·82–1·81)
1·28 (0·87–1·88)
1·31 (0·97–1·77)
1·39 (1·04–1·85)
1·34 (1·07–1·68)
1·35 (1·09–1·68)
2·97 (1·31–6·74)
2·89 (1·55–5·37)
0·99 (0·74–1·33)
1·09 (0·82–1·44)
1·11 (0·92–1·34)
1·11 (0·93–1·34)
2·02 (1·48–2·78)
2·00 (1·49–2·69)
1·69 (1·39–2·07)
1·78 (1·47–2·15)
1·00 (0·62–1·60)
1·01 (0·64–1·58)
1·07 (0·74–1·54)
1·04 (0·73–1·49)
1·08 (0·72–1·62)
1·15 (0·78–1·69)
··
··
1·10 (1·01–1·20)
1·08 (0·99–1·18)
0·77 (0·39–1·52)
0·86 (0·46–1·61)
0·99 (0·76–1·28)
1·01 (0·79–1·29)
Stratified by age–matched, gender–matched, and general practice-matched sets         Additionally adjusted for shared risk factors
Figure 1: Absolute and 
relative risks of 
cardiovascular disease 
outcomes in cancer survivors 
compared with those of 
general population controls
Cancer types or sites are 
ordered according to 
corresponding codes from the 
International Classification of 
Diseases, version 10 (ICD-10). 
Cancer sites without data had 
too few events for estimation. 
Arrowheads represent a CI 
limit lower than 0·5 or higher 
than 12. HR=hazard ratio. 
IR=incidence per 
1000 patient-years. CS=cancer 
survivors. GPC=general 
population controls. 
NHL=Non-Hodgkin 
lymphoma. 
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explored the role of cancer treatment by subdividing 
cancer survivors according to recorded receipt of chemo-
therapy and radiotherapy in the period between diagnosis 
and index date (as recorded by cancer registry, which aims 
to record the first 6 months of treatments) and estimating 
separate hazard ratios (HRs) for each group. Absolute 
cardiovascular disease incidences were summarised and 
compared with expected incidences by first fitting flexible 
parametric survival models for each cancer–outcome 
combination, with exposure (cancer survivor vs control) 
included as a time-dependent effect and adjustment for all 
covariates included in our Cox models, and then predicting 
incidence over time at both levels of exposure, with all 
other covariates fixed at the mean values in the cancer 
survivor group.16 Finally, we calculated cumulative 
incidence of cardiovascular disease at 5 years from 
diagnosis in cancer survivor and control groups, allowing 
for the presence of competing risks of non-cardiovascular 
disease death.17
We did sensitivity analyses based on our primary Cox 
models. First, we repeated the analysis using only unlinked 
data from CPRD GOLD, which allowed a larger UK-wide 
population to be drawn (because only a proportion of 
CPRD has linkage available). This extended the analysis to 
the whole of the UK and to the period January, 1987, to 
June, 2017, but at the expense of a probably higher 
misclassification of cancer diagnoses and cardiovascular 
disease outcomes. Second, we repeated the analysis 
excluding people without at least two blood pressure 
measures before the index date, rather than classifying 
these individuals as normotensive (appendix pp 4–6). 
Lastly, we repeated the analysis using a more granular 
breakdown when adjusting for alcohol, in case of residual 
confounding in our initial classification (appendix pp 4–6). 
Statistical analyses were done in Stata MP, version 15.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between Jan 1, 1990, and Dec 31, 2015, 126 120 individuals 
with an incident diagnosis of a site-specific cancer of 
interest, still being followed up at least 1 year later 
were identified and matched to 630 144 controls with no 
history of cancer. 17 905 (14·2%) cancer survivors and 
106 603 (16·9%) controls were then excluded because of 
missing smoking or BMI data, leaving 631 756 individuals 
in the final analysis cohort (figure 2, table 1, appendix 
p 8). 115 886 (18·3%) individuals were still under follow-
up at least 10 years after diagnosis (16 428 [15·2%] of 
108 215 cancer survivors and 99 458 [19·0%] of 
523 541 controls). Baseline smoking, hypertension, pre-
vious history of cardiovascular disease, and chronic 
Figure 2: Study cohort profile for primary analysis
Where multiple exclusion reasons are listed, some patients met more than one listed criteria. BMI=body-mass 
index. IMD=Index of multiple deprivation. *Index date was 1 year after date of diagnosis. 
4 303 694 potentially eligible patients 
409 063 patients with a cancer diagnosis 
208 310 patients with incident cancer
3 894 631 had no record of cancer 
421 younger than 18 years at first cancer 
diagnosis 
207 889 aged 18 years or older at diagnosis
137 851 cancer survivors
126 150 with cancer site included in study
126 120 cancer survivors with matched controls
108 215 cancer survivors included in the primary 
analysis 
65 964 follow-up ended before index date* 
8098 study ended before index date*
First record of cancer
1561 history of cancer
7070 secondary malignancy
21 965 unspecified cancer site
574 breast, ovarian, uterine, or cervical 
cancer in men
11 prostate cancer in women
86 835 before start of research quality 
follow-up
13 936 in the first year after start of 
research quality follow-up
25 017 less than 1 year before study start
73 192 after end of research quality 
follow-up
9972 after study end
678 at least one cancer with missing event 
date
11 701 site of first cancer not included in study
30 without matched controls
6976 missing smoking status
16 408 missing BMI
94 missing IMD
630 144 matched controls
523 541 matched controls included in the 
primary analysis
50 416 missing smoking status
98 021 missing BMI
486 missing IMD
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kidney disease were marginally more prevalent in cancer 
survivors than in matched controls, whereas prevalence 
of overweight and obesity was similar between groups 
and prevalence of heavy drinking was lower in cancer 
survivors than in controls. Baseline characteristics of the 
matched cohorts specific for individual cancer sites are 
presented in the appendix (pp 9–28).
We calculated incidences and cause-specific HRs 
adjusted for age and sex alone and then additionally for 
shared risk factors (figure 1). Adjustment for shared risk 
factors had little effect on HRs. In adjusted models, 
we observed strong evidence (p<0·01) of increased risk of 
incident venous thromboembolism in survivors of 18 of 
20 cancers compared with that of general population 
controls, as well as increased risks of heart failure or 
cardiomyopathy (in ten of 20 cancers), arrhythmia (eight of 
20), pericarditis (eight of 15 cancers with enough data for 
estimation), coronary artery disease (five of 20 cancers), 
stroke (five of 20), and valvular heart disease (three of 
18 cancers with enough data; figure 1). Survivors of 
haematological malignancies had increased risks across all 
of these outcomes, whereas the pattern of risks was more 
varied for survivors of other types of cancer. For peripheral 
vascular disease, we found no strong evidence of asso-
ciation and the observed HRs were in both directions. 
Results for component outcomes of venous thrombo-
embolism, heart failure or cardiomyopathy, and coronary 
artery disease were broadly similar to those of the grouped 
outcomes, but with lower statistical power (appendix 
pp 29–30).
For the coronary artery disease and stroke outcomes, we 
found little statistical evidence of effect modification by 
any of the factors assessed (appendix pp 31–32). We found 
strong evidence that the increased risk of heart failure after 
non-Hodgkin lymphoma was more pronounced at 
Cancer survivors Controls
Total number of patients 108 215 523 541
Time from cancer diagnosis or baseline to end of follow-up
Mean (SD) 5·7 (4·1) 6·4 (4·2)
Median (IQR) 4·5 (2·5–7·9) 5·4 (3·1–8·8)
Range 1·0–26·5 1·0–26·6
Total person-years included* 
(million years)
0·507 2·839
Age (years)†
Mean (SD) 66·1 (13·3) 66·0 (13·2)
Median (IQR) 67·0 
(58·0–76·0)
67·0 
(58·0–76·0)
Age (years)‡
18–59 31 057 (28·7%) 150 257 (28·7%)
60–79 60 347 (55·8%) 293 080 (56·0%)
≥80 16 811 (15·5%) 80 204 (15·3%)
Sex†‡
Men 51 541 (47·6%) 245 760 (46·9%)
Women 56 674 (52·4%) 277 781 (53·1%)
Index of Multiple Deprivation quintile (patient area)‡§¶
1 (least deprived) 27 755 (25·6%) 133 023 (25·4%)
2 25 607 (23·7%) 123 322 (23·6%)
3 22 926 (21·2%) 111 594 (21·3%)
4 17 902 (16·5%) 87 408 (16·7%)
5 (most deprived) 14 025 (13·0%) 68 194 (13·0%)
Year of cancer diagnosis†‡
1989–98 11 277 (10·4%) 53 298 (10·2%)
1999–2003 24 487 (22·6%) 117 541 (22·5%)
2004–08 37 369 (34·5%) 181 127 (34·6%)
2009–14 35 082 (32·4%) 171 575 (32·8%)
Smoking status‡¶
Non-smoker 47 682 (44·1%) 245 275 (46·8%)
Current smoker 19 433 (18·0%) 89 509 (17·1%)
Ex-smoker 41 100 (38·0%) 188 757 (36·1%)
Heavy drinker¶ 3806 (3·5%) 22 457 (4·3%)
Body-mass index‡¶
Underweight 1850 (1·7%) 8491 (1·6%)
Healthy weight 40 393 (37·3%) 196 789 (37·6%)
Overweight 42 060 (38·9%) 203 457 (38·9%)
Obese 23 912 (22·1%) 114 804 (21·9%)
Diabetes¶ 11 862 (11·0%) 55 091 (10·5%)
Hypertension‡¶ 26 246 (24·3%) 116 313 (22·2%)
Previous cardiovascular 
disease‡¶||
32 826 (30·3%) 151 436 (28·9%)
Cardiovascular treatments¶
Statins 25 947 (24·0%) 123 947 (23·7%)
β blockers 17 316 (16·0%) 83 748 (16·0%)
Angiotensin converting 
enzyme inhibitors
19 782 (18·3%) 93 542 (17·9%)
Angiotensin II receptor 
blockers
7618 (7·0%) 34 425 (6·6%)
Non-steroidal 
anti-inflammatory drugs
11 940 (11·0%) 52 875 (10·1%)
(Table 1 continues in next column)
Cancer survivors Controls
(Continued from previous column)
Previous migraine¶ 7125 (6·6%) 34 313 (6·6%)
Chronic kidney disease¶ 16 977 (15·7%) 71 655 (13·7%)
Data are n (%) and represent status at cancer diagnosis date for survivors, with the 
same date used for matched controls (baseline), unless specified otherwise. 
Number of patients by cancer type or site (with International Classification of 
Diseases codes, version 10): 1584 oral cavity (C00–06), 1794 oesophageal (C15), 
1507 stomach (C16), 14 216 colorectal (C18–20), 554 liver (C22), 864 pancreas 
(C25), 5369 lung (C34), 7098 malignant melanoma (C43), 25 633 breast (C50), 
1209 cervix (C53), 3440 uterus (C54–55), 2710 ovaries (C56), 20 709 prostate 
(C61), 2197 kidney (C64), 7712 bladder (C67), 906 CNS (>C71–72), 1028 thyroid 
(C73), 4423 non-Hodgkin lymphoma (C82–85), 1843 multiple myeloma (C90), 
3419 leukaemia (C91–95). *Index date to end of follow-up. †Matching variable. 
‡Interactions investigated. §Index of multiple deprivation is an area-based proxy 
for socioeconomic status. ¶Shared risk factor; additional variables for specific 
cancers include hysterectomy and hormone replacement therapy (female-specific 
cancers), chronic liver disease (liver cancer), immunosuppression (non-Hodgkin 
lymphoma), and systemic sclerosis and chronic obstructive pulmonary disease 
(lung cancer). ||34% of cancer survivors and 31% of controls had a history of 
previous cardiovascular disease at the index date (1 year after diagnosis or baseline). 
Table 1: Characteristics of cancer survivors and matched general 
population controls (all cancer sites)
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younger ages and in individuals with no previous 
cardiovascular disease or hypertension than in older 
people or in individuals with a history of those conditions 
(figure 3); similar patterns by age were seen for breast and 
lung cancer (appendix p 33). We found evidence of a more 
pronounced increased risk of arrhythmia after colorectal 
cancer and non-Hodgkin lymphoma in overweight or 
obese individuals compared with that of patients with 
lower weight (appendix p 34). Lastly, we found strong 
evidence that younger people and those with no history of 
cardiovascular disease had the greatest increased risk of 
venous thromboembolism after breast and colorectal 
cancer. These risks attenuated with time, but remained 
significantly elevated more than 5 years after diagnosis 
(figure 3); similar patterns were seen for several other 
cancer sites, although with more statistical uncertainty 
(appendix p 35). In a post-hoc analysis of cancers associated 
with increased risk of venous thromboembolism more 
than 5 years after diagnosis, we introduced another time 
category split at 10 years: risk of venous thromboem-
Figure 3: Relative risk of cardiovascular disease outcomes in cancer survivors compared with that of the general population, with effect modification 
(selected models)
pint=p for interaction (likelihood ratio test). CVD=cardiovascular disease. HR=hazard ratio.
Men
Sex
Age
Deprivation
Overweight or obese
Smoker
Previous CVD
Hypertension
Years since diagnosis
Years
Women
<60 years
60–79 years
≥80 years 
Lower
Higher
Never
Ever
No
Yes
No
Yes
No
Yes
1–2
>2–5
>5
1989–2003
2004–08
2009–14
Men
Sex
Age
Deprivation
Overweight or obese
Smoker
Previous CVD
Hypertension
Years since diagnosis
Years
Women
<60 years
60–79 years
≥80 years 
Lower
Higher
Never
Ever
No
Yes
No
Yes
No
Yes
1–2
>2–5
>5
1989–2003
2004–08
2009–14
Age
Deprivation
Overweight or obese
Smoker
Previous CVD
Hypertension
Years since diagnosis
Years
<60 years
60–79 years
≥80 years 
Lower
Higher
Never
Ever
No
Yes
No
Yes
No
Yes
1–2
>2–5
>5
1989–2003
2004–08
2009–14
1·84 (1·49–2·26)
2·05 (1·65–2·56)
4·38 (2·74–7·01)
1·96 (1·62–2·38)
1·40 (1·04–1·88)
2·07 (1·72–2·49)
1·67 (1·25–2·23)
1·88 (1·47–2·41)
1·97 (1·61–2·42)
2·25 (1·77–2·84)
1·71 (1·38–2·12)
2·52 (2·05–3·09)
1·36 (1·06–1·74)
2·32 (1·92–2·80)
1·32 (0·99–1·76)
2·02 (1·48–2·75)
1·61 (1·27–2·04)
2·37 (1·83–3·07)
2·02 (1·62–2·51)
1·90 (1·49–2·42)
1·79 (1·20–2·66)
0·47
0·0003
0·23
0·78
0·11
0·0003
0·0020
0·085
0·86
0·5 1·0 2·0 4·0 8·0
0·5 1·0 2·0
HR (95% CI)
HR (95% CI)
4·0 8·0
Heart failure or cardiomyopathy risk after non-Hodgkin lymphoma 
 
2·77 (2·37–3·23)
1·83 (1·63–2·05)
1·48 (1·16–1·87)
2·06 (1·85–2·29)
1·91 (1·62–2·25)
2·02 (1·74–2·36)
2·01 (1·80–2·24)
2·02 (1·79–2·29)
2·00 (1·75–2·29)
2·23 (2·02–2·47)
1·46 (1·20–1·77)
2·13 (1·92–2·36)
1·74 (1·45–2·08)
3·12 (2·58–3·78)
2·23 (1·95–2·54)
1·45 (1·26–1·67)
1·92 (1·70–2·17)
2·08 (1·80–2·40)
2·20 (1·75–2·77)
 <0·0001
0·46
0·93
0·91
 0·0002
0·065
 <0·0001
0·51
Venous thromboembolism risk after breast cancer
2·37 (2·04–2·74)
2·60 (2·22–3·04)
4·80 (3·54–6·50)
2·51 (2·20–2·86)
1·54 (1·20–1·97)
2·48 (2·18–2·83)
2·45 (1·99–3·01)
2·52 (2·10–3·04)
2·44 (2·13–2·81)
2·55 (2·15–3·03)
2·41 (2·07–2·81)
2·78 (2·44–3·18)
1·89 (1·53–2·34)
2·72 (2·39–3·10)
1·91 (1·53–2·39)
4·17 (3·39–5·13)
2·77 (2·35–3·26)
1·39 (1·14–1·69)
2·09 (1·78–2·45)
2·56 (2·15–3·04)
3·64 (2·81–4·71)
0·39
 <0·0001
0·92
0·79
0·65
0·0035
0·010
 <0·0001
0·0015
Venous thromboembolism risk after colorectal cancer
pint
pint
pint
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bolism remained elevated 10 years after diagnosis for 
colorectal cancer (HR 1·61, 95% CI 1·10–2·35; p=0·014), 
non-Hodgkin lymphoma (3·94, 1·65–9·43; p=0·0020), 
and malignant melanoma (2·00, 1·14–3·49; p=0·015), but 
not for breast, bladder, or prostate cancers; there were too 
few events 10 years after diagnosis of lung cancer and 
leukaemia for estimation.
Absolute venous thromboembolism incidence was 
highest closer to the time of cancer diagnosis and 
reduced over time, as did incidence of arrhythmia after 
lung cancer, whereas heart failure or cardiomyopathy 
incidence increased with time after diagnosis (figure 4, 
appendix pp 36–38). Absolute excess risks were generally 
higher in the oldest age group than in younger groups: 
for example, in survivors of non-Hodgkin lymphoma 
5 years after diagnosis, patients younger than 60 years 
had absolute excess risk of heart failure or cardiomyopathy 
of 0·4% per year (95% CI 0·2–0·6), whereas patients 
aged 80 years or older had excess risk of 2·1% per year 
(0·8–3·3); however, the opposite pattern was seen in 
survivors of lung cancer (table 2). 5-year cumulative 
incidences in the presence of the competing risk of 
non-cardiovascular disease death, stratified by age, are 
presented in the appendix (p 39).
In exploratory analyses in which cancer survivors were 
grouped according to treatment methods recorded in the 
registry data, we found evidence of a substantially elevated 
risk of venous thromboembolism in all cancer survivor 
groups compared with that of the general population, 
regardless of treatment. This risk was most pronounced 
in patients receiving chemo therapy. Chemotherapy use 
also seemed to be the key driver of heart failure or 
cardiomyopathy risk after breast cancer (appendix p 40). 
In sensitivity analyses using primary care data alone, 
effect estimates in the main Cox models were broadly 
similar, with slight movement towards the null for some 
exposure–outcome combinations, consistent with the 
known direction of bias resulting from non-differential 
misclassification.18 The use of more sensitive covariate 
definitions for hypertension and alcohol use made little 
difference to the effect estimates (appendix pp 41–44).
Discussion
In this comprehensive assessment of the risk of cardio-
vascular disease in cancer survivors compared with that 
of general population controls, we found increased risks 
of cardiovascular diseases in the years after diagnosis of 
most site-specific cancers. We observed large increases in 
the risk of venous thromboembolism in survivors of 
18 of 20 cancer types. This risk attenuated over time but 
remained elevated for at least 5 years after diagnosis for 
most cancer types. We also observed increased risks of 
heart failure or cardiomyopathy in survivors of ten of 
20 site-specific cancer types, including greater than 
Figure 4: Absolute incidence of cardiovascular disease outcomes compared with expected incidence by age group and time since diagnosis
Incidence in cancer survivors and expected incidence calculated by fitting flexible parametric survival models with exposure (cancer survivor vs control), covariates, 
and interaction between exposure and time since diagnosis and by predicting incidence for exposed or unexposed at the mean value of covariates in cancer survivors. 
Cancer sites defined by corresponding codes from the International Classification of Diseases, version 10. *The group of cancer survivors aged 60–79 years had 
incidence similar to that of the group aged ≥80 years, resulting in a seemingly absent blue line in the graph. 
0 2 4 6 8 10 12
0
2
4
6
8
10
In
cid
en
ce
 (p
er
 1
00
 p
er
so
n-
ye
ar
s)
Time since cancer diagnosis or baseline (years)
0 2 4 6 8 10 12
Time since cancer diagnosis or baseline (years)
0 2 4 6 8 10 12
Time since cancer diagnosis or baseline (years)Venous thromboembolism 
after lung cancer (C34)  
Venous thromboembolism 
after uterine cancer (C54–55)  
0
2
4
6
8
10
In
cid
en
ce
 (p
er
 1
00
 p
er
so
n-
ye
ar
s)
Arrhythmia after lung cancer (C34) Heart failure or cardiomyopathy
after non-Hodgkin lymphoma (C82–85)
Venous thromboembolism 
after colorectal cancer (C18–20)*  
Age 18–59 years, cancer survivors
Age 60–79 years, cancer survivors
Age ≥80 years, cancer survivors
Age 18–59 years, expected incidence
Age 60–79 years, expected incidence
Age ≥80 years, expected incidence
Articles
10 www.thelancet.com   Published online August 20, 2019   http://dx.doi.org/10.1016/S0140-6736(19)31674-5
18–59 years 60–79 years ≥80 years
Observed 
incidence
Expected 
incidence
Excess (95% CI) Observed 
incidence
Expected 
incidence
Excess (95% CI) Observed 
incidence
Expected 
incidence
Excess (95% CI)
Arrhythmia incidence at 5 years
Colorectal (C18–20) 1·2 1·0 0·2 (–0·0 to 0·5) 2·5 2·3 0·2 (–0·0 to 0·5) 4·2 4·6 –0·4 (–1·1 to 0·3)
Lung (C34) 2·7 1·0 1·7 (0·8 to 2·6) 3·9 2·5 1·4 (0·6 to 2·2) 6·1 5·4 0·7 (–1·4 to 2·7)
Melanoma (C43) 1·0 0·8 0·1 (–0·1 to 0·3) 2·1 2·0 0·1 (–0·3 to 0·4) 3·9 4·0 –0·2 (–1·2 to 0·8)
Breast (C50) 1·1 1·0 0·1 (–0·0 to 0·2) 1·9 1·8 0·1 (–0·1 to 0·2) 3·8 3·7 0·1 (–0·4 to 0·6)
Uterus (C54–55) 1·4 1·2 0·2 (–0·2 to 0·6) 2·0 2·1 –0·0 (–0·5 to 0·4) 5·1 4·1 1·0 (–0·9 to 2·9)
Prostate (C61) 1·1 1·1 –0·0 (–0·3 to 0·2) 2·6 2·5 0·1 (–0·1 to 0·3) 5·5 5·0 0·5 (–0·2 to 1·1)
Bladder (C67) 1·1 1·1 0·0 (–0·3 to 0·4) 2·8 2·5 0·3 (–0·1 to 0·7) 5·1 4·9 0·3 (–0·7 to 1·2)
NHL (C82–85) 1·3 0·8 0·5 (0·1 to 0·9) 2·9 2·1 0·8 (0·2 to 1·4) 5·7 4·4 1·4 (–0·3 to 3·0)
Leukaemia (C91–95) 1·1 1·0 0·2 (–0·2 to 0·6) 2·6 2·4 0·2 (–0·4 to 0·8) 3·9 5·0 –1·1 (–2·4 to 0·2)
Coronary artery disease incidence at 5 years
Colorectal (C18–20) 0·7 0·6 0·1 (–0·1 to 0·2) 1·3 1·4 –0·2 (–0·4 to 0·0) 2·2 2·3 –0·1 (–0·5 to 0·4)
Lung (C34) 1·3 0·7 0·6 (0·0 to 1·2) 2·0 1·7 0·3 (–0·3 to 0·9) 2·9 2·7 0·2 (–1·2 to 1·5)
Melanoma (C43) 0·3 0·3 0·0 (–0·1 to 0·1) 1·2 0·9 0·3 (0·0 to 0·6) 2·1 1·9 0·2 (–0·6 to 1·0)
Breast (C50) 0·3 0·3 –0·0 (–0·1 to 0·0) 0·8 0·9 –0·1 (–0·2 to 0·0) 1·3 1·7 –0·4 (–0·7 to –0·1)
Uterus (C54–55) 0·4 0·4 –0·0 (–0·3 to 0·2) 0·7 1·0 –0·4 (–0·6 to –0·1) 2·3 1·9 0·4 (–0·8 to 1·6)
Prostate (C61) 0·9 1·0 –0·1 (–0·4 to 0·1) 1·8 1·8 0·1 (–0·1 to 0·2) 2·6 2·7 –0·1 (–0·5 to 0·3)
Bladder (C67) 1·1 0·7 0·4 (0·1 to 0·7) 2·0 1·7 0·4 (0·0 to 0·7) 2·7 2·6 0·2 (–0·5 to 0·8)
NHL (C82–85) 0·8 0·4 0·3 (0·1 to 0·6) 1·8 1·3 0·5 (0·1 to 1·0) 2·2 2·0 0·2 (–0·7 to 1·2)
Leukaemia (C91–95) 0·9 0·6 0·3 (–0·1 to 0·7) 1·8 1·5 0·4 (–0·2 to 0·9) 3·1 2·0 1·1 (–0·1 to 2·2)
Heart failure or cardiomyopathy incidence at 5 years
Colorectal (C18–20) 0·3 0·3 0·0 (–0·1 to 0·1) 1·0 1·1 –0·0 (–0·2 to 0·1) 2·6 3·0 –0·4 (–0·9 to 0·1)
Lung (C34) 1·1 0·3 0·8 (0·3 to 1·3) 2·2 1·3 0·8 (0·3 to 1·4) 4·1 4·1 0·1 (–1·5 to 1·6)
Melanoma (C43) 0·1 0·1 –0·0 (–0·1 to 0·0) 0·6 0·7 –0·1 (–0·3 to 0·1) 2·3 2·5 –0·2 (–0·9 to 0·5)
Breast (C50) 0·2 0·1 0·1 (0·1 to 0·2) 0·7 0·7 0·1 (–0·0 to 0·2) 2·1 2·3 –0·1 (–0·5 to 0·2)
Uterus (C54–55) 0·2 0·2 –0·0 (–0·1 to 0·1) 0·7 0·8 –0·1 (–0·3 to 0·2) 3·3 2·7 0·6 (–0·7 to 1·9)
Prostate (C61) 0·4 0·4 –0·1 (–0·2 to 0·1) 1·4 1·4 0·0 (–0·1 to 0·2) 4·0 3·6 0·3 (–0·2 to 0·8)
Bladder (C67) 0·4 0·3 0·1 (–0·1 to 0·3) 1·7 1·5 0·3 (0·0 to 0·5) 4·2 3·9 0·3 (–0·5 to 1·1)
NHL (C82–85) 0·6 0·2 0·4 (0·2 to 0·6) 1·8 0·9 1·0 (0·6 to 1·3) 4·6 2·5 2·1 (0·8 to 3·3)
Leukaemia (C91–95) 0·5 0·2 0·3 (0·0 to 0·5) 1·6 1·1 0·5 (0·1 to 0·9) 3·8 3·5 0·4 (–0·8 to 1·5)
Stroke incidence at 5 years
Colorectal (C18–20) 0·4 0·3 0·1 (–0·0 to 0·2) 1·1 1·1 –0·0 (–0·2 to 0·1) 2·1 2·5 –0·4 (–0·8 to 0·0)
Lung (C34) 1·1 0·3 0·8 (0·4 to 1·3) 1·6 1·3 0·4 (–0·0 to 0·8) 2·6 2·6 0·0 (–1·0 to 1·1)
Melanoma (C43) 0·3 0·2 0·1 (–0·0 to 0·2) 0·8 0·8 –0·0 (–0·2 to 0·2) 1·9 2·1 –0·2 (–0·9 to 0·5)
Breast (C50) 0·2 0·2 0·0 (–0·0 to 0·1) 0·8 0·7 0·0 (–0·1 to 0·1) 2·0 2·1 –0·1 (–0·5 to 0·2)
Uterus (C54–55) 0·2 0·2 –0·0 (–0·2 to 0·1) 0·7 0·8 –0·0 (–0·3 to 0·2) 1·8 1·7 0·1 (–0·8 to 1·0)
Prostate (C61) 0·6 0·5 0·1 (–0·0 to 0·3) 1·3 1·2 0·0 (–0·1 to 0·2) 2·6 2·5 0·1 (–0·3 to 0·5)
Bladder (C67) 0·4 0·3 0·1 (–0·1 to 0·3) 1·4 1·3 0·1 (–0·2 to 0·3) 3·0 2·8 0·2 (–0·5 to 0·8)
NHL (C82–85) 0·4 0·2 0·2 (0·0 to 0·4) 1·2 1·0 0·2 (–0·1 to 0·6) 2·9 2·4 0·5 (–0·5 to 1·6)
Leukaemia (C91–95) 0·6 0·3 0·3 (0·1 to 0·6) 1·2 0·9 0·3 (–0·1 to 0·6) 2·0 2·3 –0·3 (–1·1 to 0·5)
Venous thromboembolism incidence at 1 year
Colorectal (C18–20) 1·5 0·1 1·4 (0·9 to 1·8) 2·0 0·3 1·7 (1·2 to 2·1) 2·0 0·6 1·4 (0·8 to 1·9)
Lung (C34) 4·5 0·2 4·3 (2·9 to 5·8) 3·8 0·5 3·3 (2·4 to 4·2) 3·1 0·8 2·3 (0·9 to 3·7)
Melanoma (C43) 0·3 0·1 0·3 (0·1 to 0·4) 0·8 0·2 0·6 (0·2 to 1·0) 1·0 0·4 0·5 (–0·1 to 1·2)
Breast (C50) 0·7 0·1 0·6 (0·5 to 0·8) 1·1 0·3 0·9 (0·7 to 1·1) 1·7 0·5 1·2 (0·7 to 1·6)
Uterus (C54–55) 1·3 0·2 1·2 (0·4 to 2·0) 2·3 0·3 1·9 (0·8 to 3·1) 3·0 0·8 2·3 (0·3 to 4·2)
Prostate (C61) 0·4 0·2 0·2 (0·1 to 0·4) 0·9 0·3 0·5 (0·3 to 0·8) 1·3 0·5 0·8 (0·3 to 1·2)
Bladder (C67) 1·2 0·1 1·1 (0·5 to 1·7) 1·9 0·3 1·6 (0·9 to 2·4) 1·7 0·5 1·2 (0·5 to 1·9)
NHL (C82–85) 0·7 0·1 0·6 (0·0 to 1·2) 1·4 0·3 1·1 (0·0 to 2·1) 1·7 0·7 1·0 (–0·4 to 2·4)
Leukaemia (C91–95) 0·4 0·1 0·3 (–0·0 to 0·6) 0·8 0·4 0·4 (–0·2 to 0·9) 0·8 0·7 0·2 (–0·6 to 0·9)
(Table 2 continues on next page)
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50% increases in risk after haematological, oesophageal, 
lung, kidney, and ovarian cancers and increased risks of 
arrhythmia, pericarditis, coronary artery disease, stroke, 
and valvular heart disease for multiple cancer sites. 
Survivors of haematological malignancies had increased 
risks across all these outcomes, but the pattern of risks 
varied for other cancer sites. Adjustment for shared risk 
factors for cancer and cardiovascular disease had little 
effect on associations. Relative risks for heart failure or 
cardio myopathy and venous thromboembolism associated 
with cancer survival were most pronounced in younger 
ages and in individuals with no previous cardiovascular 
disease or hypertension (ie, those with the lowest baseline 
risk); however, higher absolute effects were often observed 
in older individuals.
Our finding of substantial variability by cancer site of 
associations between cancer survival and subsequent 
cardiovascular disease is consistent with a US study19 
comparing risks for a composite cardiovascular disease 
outcome between cohorts with site-specific cancers and 
controls without a history of cancer. This study showed 
significantly increased cardiovascular disease risks for 
breast and lung cancers, malignant melanoma, and 
non-Hodgkin lymphoma and an unexpected reduced 
risk for prostate cancer; no associations were found for 
the remaining nine cancers studied, including for 
bladder cancer.19 The composite outcome in the US 
study included ischaemic heart disease, heart failure or 
cardiomyopathy, and stroke. In our study, we analysed 
these three outcomes individually, and our results 
were consistent with the US study findings, except that 
we did not replicate the inverse association in sur-
vivors of prostate cancer, and we found the risk of 
all three outcomes to be increased after bladder cancer. 
This discrepancy might reflect differences in the 
profiles of patients with bladder cancer between the 
two countries, differences in treatment protocols,20 or 
chance variation.
Most previous studies have focused on survivors of 
a single, site-specific cancer, most commonly breast 
cancer (appendix pp 47–59). Although consistent 
findings exist of increased heart failure risk in patients 
after breast cancer, mainly driven by patients receiving 
anthracyclines, trastuzumab, or both,19,21 the risks of 
coronary artery disease in this population are less clear. 
We found a lower risk of coronary artery disease in 
survivors of breast cancer compared with that of controls, 
in line with a US study22 that found reductions in 
myocardial infarction risk in this population. By contrast, 
a Danish study11 in people diagnosed at age 15–39 years 
observed a higher risk of myocardial infarction in 
survivors of breast cancer compared with that of controls, 
whereas most other studies19,21,23–26 found no difference 
in either direction. A reduced risk of coronary artery 
disease in survivors of breast cancer might be driven by 
socioeconomic factors;27 these can vary by setting, with a 
higher socioeconomic level being associated with a 
higher risk of breast cancer in the UK. In our study, we 
matched by general practice, which would give some 
control for geographical area-based socioeconomic 
factors and, in fully adjusted models, we also included 
the Index of Multiple Depri vation, a patient postcode-
based deprivation index; however, we were not able to 
adjust for socioeconomic status at the more granular 
household or individual level. Several studies11,28,29 have 
shown increased risks of venous thromboembolism in 
patients after breast cancer, including a study30 that 
found increased risks during and immediately after 
treatment. Strikingly, in our study, venous throm-
boembolism risk was elevated in patients for at least 
5 years after diagnosis compared with that of controls 
with no history of cancer, even among patients with 
18–59 years 60–79 years ≥80 years
Observed 
incidence
Expected 
incidence
Excess (95% CI) Observed 
incidence
Expected 
incidence
Excess (95% CI) Observed 
incidence
Expected 
incidence
Excess (95% CI)
(Continued from previous page)
Venous thromboembolism incidence at 5 years
Colorectal (C18–20) 0·8 0·2 0·6 (0·4 to 0·7) 1·0 0·5 0·5 (0·3 to 0·6) 1·0 1·0 0·0 (–0·2 to 0·3)
Lung (C34) 1·7 0·2 1·5 (0·8 to 2·2) 1·4 0·6 0·9 (0·4 to 1·4) 1·2 0·9 0·2 (–0·4 to 0·9)
Melanoma (C43) 0·3 0·1 0·1 (0·0 to 0·2) 0·6 0·5 0·2 (–0·0 to 0·4) 0·8 0·9 –0·2 (–0·6 to 0·2)
Breast (C50) 0·5 0·2 0·4 (0·3 to 0·4) 0·8 0·4 0·4 (0·3 to 0·5) 1·2 0·8 0·4 (0·1 to 0·6)
Uterus (C54–55) 0·5 0·2 0·3 (0·1 to 0·5) 0·9 0·5 0·4 (0·1 to 0·7) 1·2 1·0 0·1 (–0·6 to 0·8)
Prostate (C61) 0·4 0·2 0·2 (0·0 to 0·3) 0·9 0·5 0·4 (0·2 to 0·5) 1·3 0·8 0·5 (0·2 to 0·8)
Bladder (C67) 0·6 0·2 0·3 (0·1 to 0·5) 0·9 0·5 0·3 (0·2 to 0·5) 0·8 0·9 –0·1 (–0·4 to 0·2)
NHL (C82–85) 0·5 0·2 0·3 (0·1 to 0·5) 0·9 0·5 0·4 (0·1 to 0·7) 1·1 1·0 0·0 (–0·6 to 0·6)
Leukaemia (C91–95) 0·7 0·2 0·5 (0·1 to 0·8) 1·2 0·6 0·6 (0·2 to 1·0) 1·3 1·0 0·3 (–0·3 to 1·0)
Data are absolute incidence (from time of cancer diagnosis) of cardiovascular disease outcomes per 100 person-years (or equivalently risk [%] per year). Cancer codes from the International Classification of 
Diseases, version 10. Incidence in cancer survivors and expected incidence calculated by fitting flexible parametric survival models with exposure (cancer survivor vs control), covariates, and interaction between 
exposure and time since diagnosis and predicting incidence for exposed or unexposed at the mean value of covariates in cancer survivors. NHL=non-Hodgkin lymphoma.
Table 2: Absolute incidence of cardiovascular disease outcomes at specific timepoints after cancer diagnosis compared with expected incidence, by age group
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no record of receiving chemotherapy, suggesting long-
term effects of the underlying malignancy, long-term 
endocrine therapies, or residual confounding by shared 
risk factors.
A major strength of our study was that the size and 
breadth of the linked data sources enabled us to investigate 
associations in granular detail. The importance of this is 
evident in the observed heterogeneity in the associ ations 
by cancer site and specific cardiovascular disease out-
comes, showing that analyses of composite outcomes and 
all-cancer exposures can mask important variation. We 
had the data and statistical power to do a comprehensive 
analysis of medium-term and long-term cardiovascular 
disease risks for survivors of 20 site-specific cancers and to 
investigate effect modifications for the nine most common 
cancers and key cardiovascular disease outcomes. The use 
of consistent methodology across a wide range of cancers 
and outcomes gives confidence that the observed patterns 
of risk reflect real phenomena, rather than methodological 
artefacts. Multiple validation studies31–33 have established 
the strengths of using CPRD GOLD data linked to 
secondary care data sources to identify disease phenotypes, 
including for cancer and cardiovascular disease. We used 
multiple data linkages to maximise capture of cancer 
exposures and cardiovascular disease outcomes and to 
minimise misclassification. CPRD GOLD data have been 
shown to be representative of the general UK population 
on key demographics; therefore our results are generali-
sable to the UK and similar settings.12
Nonetheless, our study has important limitations. 
Although we could broadly categorise some groups of 
cancer survivors according to key treatment methods 
recorded, and thus begin to explore the role of treatment 
in driving cardiovascular disease risks, we had no 
information on specific chemotherapy drugs or doses 
received and no details on fields or doses of radiotherapy 
exposure. For several cancer sites, cancer registration 
data were too incomplete to be used at all. Where data 
were available, power was insufficient to assess whether 
the time course of cardiovascular disease in cancer 
survivors differed according to the initial treatments 
received. Cancer registry treatment data are most 
complete for treatments received during the first 
6 months after diagnosis, with less information after 
this, and we had no reliable information on cancer 
recurrence, which could have been an important 
predictor of further cardiotoxic treatment and sub-
sequent increased cardiovascular disease risk. Stage 
and grade data were not sufficiently complete across the 
study period to assess differences by severity of cancer 
at diagnosis. Our prescription data came from primary 
care alone and thus, we could not assess trends over 
time in hospital prescribing of drugs that might be 
given to mitigate chemotherapy-induced cardiotoxicities, 
such as anti-hypertensive drugs or dexrazoxane, in the 
context of increasing awareness of the cardiovascular 
risks in patients after cancer. The greater use of such 
cardioprotective drugs in patients with pre-existing 
cardiovascular disease might explain the lower HRs 
observed in that group for some outcomes. We did not 
have sufficiently detailed data to classify the stroke 
outcome as ischaemic or haemorrhagic, which could 
have been important given the observed heterogeneity 
of associations between cancer survival and different 
cardiovascular disease outcomes. Some individuals had 
missing BMI and smoking data; our complete-case 
analysis assumed that associations between cancer and 
cardiovascular disease, conditional on covariates, do 
not differ between included and excluded individuals,34 
which we have no reason to doubt. We estimated 
associations between multiple cancer sites and cardio-
vascular disease outcomes, increasing the risk of 
false positive associations; therefore, individual effect 
estimates with wide CIs that are close to the null should 
be interpreted cautiously. Finally, we did not have 
reliable information on potentially important variables 
including dyslipidaemia, family history of cardiovascular 
disease, ethnicity, diet, alcohol intake, exercise, and age 
at menopause (for gynaecological cancers).
The causes of increased cardiovascular disease risks in 
these patient groups are likely to be varied, but our analyses 
suggest that cancer treatments, particularly chemotherapy, 
are likely to play a more prominent role than shared risk 
factors such as smoking and excess weight. Surgery-
associated phenomena and mechanisms directly related to 
cancer biology might also play a part, for example in the 
increased risk of stroke in survivors of central nervous 
system cancers. The best-known cardiotoxicity related to 
cancer treatment is that of anthracycline chemotherapy 
drugs, which have been found to substantially increase 
risk of reduced left ventricular ejection fraction and 
subsequent clinical heart failure.35 Trastuzumab is also 
known to cause left ventricular dysfunction and is likely to 
have driven part of the observed elevated heart failure risk 
in patients after breast cancer.36 Chest radiotherapy 
involving the heart has been shown to increase risks of 
coronary artery disease in a dose-dependent manner,37 
which might explain the increased risks of this outcome 
in patients after oesophageal cancer, lung cancer, and 
haematological malignancies that might require chest 
irradiation. Platinum-containing chemotherapies used 
in lung, oesophageal, and other cancers might also play 
a role.38 However, more broadly, insufficient evidence 
exists on the specific long-term cardiotoxicities of 
modern systemic anti-cancer drugs, radiotherapy with 
modern techniques, and the interactions between them. 
Registration of anti-cancer therapies is becoming more 
widespread, with potential for linkage to other routinely 
collected data; this will begin to provide crucial long-term 
data to fill this evidence gap and enable greater delineation 
of risk drivers in follow-up studies.
Our findings might have several implications for patient 
management to improve outcomes. The relevance of 
traditional cardiovascular disease risk prediction and risk 
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minimisation for patients living after a cancer diagnosis is 
unclear. Prediction models of cardiovascular disease risk 
used in general practice typically do not include outcomes 
such as heart failure and venous thromboembolism and 
do not include cancer as a predictor. Additionally, these 
models generally ignore competing risks,39 which are 
likely to be important in a cancer survival setting: our 
analyses of cumulative incidence showed that cardio-
vascular disease burden might be influenced by both 
cancer mortality and cardiovascular disease risk. For 
example, heart failure risk was considerably elevated in 
survivors of lung cancer compared with that of general 
population controls, but a high incidence of lung cancer 
mortality meant that the 5-year cumulative incidence of 
heart failure was actually lower in our lung cancer cohort 
compared with that in general population controls, after 
we accounted for the competing risk of non-cardiovascular 
disease death. Beyond more tailored risk prediction 
modelling, screening for biomarkers or with routine 
imaging might be needed to identify cancer survivors at 
high risk of a range of cardiovascular diseases. Prevention 
at early stages is a priority because the prognosis for 
cancer survivors diagnosed with cardiovascular disease is 
particularly poor.19 Hopes have been placed on the use of 
myocardial strain, troponin, and natriuretic peptide as 
biomarkers that could identify developing heart function 
problems at an early stage.40 One difficulty with managing 
post-cancer risk of cardiovascular disease has been that 
the long-term follow-up is typically done by cancer 
specialists, leading to insufficient focus on potential 
cardiovascular disease sequelae. Cardio-oncology clinics 
that bring together oncologists, cardiologists, and 
specialist nurses are starting to appear and will help to 
address this growing clinical problem.40,41 Primary care 
physicians are also key for early prevention, and a pressing 
need exists to raise awareness among GPs of the increased 
cardiovascular disease risks in cancer survivors. In a 
survey of English GPs, only about half reported receiving 
cancer treatment summaries and only a fifth reported 
considering cancer in relation to cardiovascular health.42 
This is corroborated by a study published in 2018,43 in 
which we showed that cancer survivors were no more 
likely to receive cardio protective medications than controls 
without a history of cancer, with low uptake in both 
groups. Clearly, more and better education and aware ness 
is needed among GPs, other clinicians, and patients, 
so that preventive strategies can be considered and 
implemented, covering the extended time course during 
which our results suggest that cardiovascular disease risk 
might be elevated. Available information for clinicians 
is insufficient, and the development of comprehensive, 
evidence-based, national level guidance on cardiovascular 
considerations in cancer survival care could be prioritised 
to help optimise the care of this patient group.
In conclusion, survivors of most site-specific cancers 
had higher risks of cardiovascular disease compared with 
those of people without diagnosed cancer, with patterns 
of risk varying by cancer site and by specific cardiovascular 
disease outcome. Strategies to minimise and manage 
cardiovascular risk are needed for the growing population 
of cancer survivors.
Contributors
KB conceived the study. All authors contributed to the study design and 
protocol. HS did the data management. HS and KB did the statistical 
analysis and wrote the first draft. All authors contributed to subsequent 
drafts.
Declaration of interests
ARL reports grants and personal fees from Servier and Pfizer 
and personal fees from Novartis, Roche, Takeda, Boehringer Ingelheim, 
Amgen, Clinigen Group, Ferring Pharmaceuticals, Eli Lily, 
Bristol-Myers Squibb, and Eisai, outside the submitted work. KB reports 
grants from Wellcome and the Royal Society, during the conduct of the 
study, and grants from the Medical Research Council, the British Heart 
Foundation and Diabetes UK, outside the submitted work. LS reports 
grants from Wellcome, the Medical Research Council, National Institute 
for Health Research, GlaxoSmithKline, the British Heart Foundation, 
and Diabetes UK, outside the submitted work, and is a trustee of the 
British Heart Foundation. SS reports personal fees from Roche, 
Novartis, Eli Lilly, and Clinigen, outside the submitted work. All other 
authors declare no competing interests.
Acknowledgments
KB holds a Sir Henry Dale fellowship, jointly funded by the Wellcome 
Trust and the Royal Society (107731/Z/15/Z). This work uses data 
provided by patients and collected by the National Health Service as part 
of their care and support.
References
1 Cancer Research UK. Cancer statistics for the UK. 2019. 
https://www.cancerresearchuk.org/health-professional/cancer-
statistics-for-the-uk (accessed March 7, 2019).
2 Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC 
Position Paper on cancer treatments and cardiovascular toxicity 
developed under the auspices of the ESC Committee for Practice 
Guidelines: the Task Force for cancer treatments and 
cardiovascular toxicity of the European Society of Cardiology. 
Eur Heart J 2016; 37: 2768–801.
3 Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors 
in cardiovascular disease and cancer. Circulation 2016; 133: 1104–14.
4 Chang H-M, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. 
Cardiovascular complications of cancer therapy: best practices in 
diagnosis, prevention, and management: part 1. J Am Coll Cardiol 
2017; 70: 2536–51.
5 Chang H-M, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. 
Cardiovascular complications of cancer therapy: best practices in 
diagnosis, prevention, and management: part 2. J Am Coll Cardiol 
2017; 70: 2552–65.
6 Armenian SH, Armstrong GT, Aune G, et al. Cardiovascular 
disease in survivors of childhood cancer: insights into 
epidemiology, pathophysiology, and prevention. J Clin Oncol 2018; 
36: 2135–44.
7 Virani SA, Dent S, Brezden-Masley C, et al. Canadian Cardiovascular 
Society guidelines for evaluation and management of cardiovascular 
complications of cancer therapy. Can J Cardiol 2016; 32: 831–41.
8 Mehta LS, Watson KE, Barac A, et al. Cardiovascular disease and 
breast cancer: where these entities intersect: a scientific statement 
from the American Heart Association. Circulation 2018; 137: e30–66.
9 Henson KE, Reulen RC, Winter DL, et al. Cardiac mortality among 
200 000 five-year survivors of cancer diagnosed at 15 to 39 years 
of age: the Teenage and Young Adult Cancer Survivor Study. 
Circulation 2016; 134: 1519–31.
10 Schoormans D, Vissers PAJ, van Herk-Sukel MPP, et al. 
Incidence of cardiovascular disease up to 13 year after cancer 
diagnosis: a matched cohort study among 32 757 cancer survivors. 
Cancer Med 2018; 7: 4952–63.
11 Rugbjerg K, Mellemkjaer L, Boice JD, Køber L, Ewertz M, 
Olsen JH. Cardiovascular disease in survivors of adolescent and 
young adult cancer: a Danish cohort study, 1943–2009. 
J Natl Cancer Inst 2014; 106: dju110.
Articles
14 www.thelancet.com   Published online August 20, 2019   http://dx.doi.org/10.1016/S0140-6736(19)31674-5
12 Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: 
Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015; 
44: 827–36.
13 Padmanabhan S, Carty L, Cameron E, Ghosh RE, Williams R, 
Strongman H. Approach to record linkage of primary care data 
from Clinical Practice Research Datalink to other health-related 
patient data: overview and implications. Eur J Epidemiol 2019; 
34: 91–99.
14 NHS Digital. Read codes. 2018. https://digital.nhs.uk/services/
terminology-and-classifications/read-codes (accessed March 7, 2019).
15 Textor J, van der Zander B, Gilthorpe MS, Liśkiewicz M, 
Ellison GTH. Robust causal inference using directed acyclic graphs: 
the R package ‘dagitty’. Int J Epidemiol 2017; 45: 1887–94.
16 Lambert PC, Royston P. Further development of flexible parametric 
models for survival analysis. Stata J 2009; 9: 265–90.
17 Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival 
data in the presence of competing risks. Circulation 2016; 
133: 601–09.
18 Pearce N, Checkoway H, Kriebel D. Bias in occupational 
epidemiology studies. Occup Environ Med 2007; 64: 562–68.
19 Armenian SH, Xu L, Ky B, et al. Cardiovascular disease among 
survivors of adult-onset cancer: a community-based retrospective 
cohort study. J Clin Oncol 2016; 34: 1122–30.
20 Power NE, Izawa J. Comparison of guidelines on non-muscle 
invasive bladder cancer (EAU, CUA, AUA, NCCN, NICE). Bl Cancer 
2016; 2: 27–36.
21 Abdel-Qadir H, Thavendiranathan P, Austin PC, et al. The risk of 
heart failure and other cardiovascular hospitalizations after early 
stage breast cancer: a matched cohort study. J Natl Cancer Inst 2019; 
published online Jan 31. DOI:10.1093/jnci/djy218.
22 Jordan JH, Thwin SS, Lash TL, et al. Incident comorbidities and 
all-cause mortality among 5-year survivors of stage I and II breast 
cancer diagnosed at age 65 or older: a prospective-matched cohort 
study. Breast Cancer Res Treat 2014; 146: 401–09.
23 Ameijide A, Clèries R, Carulla M, et al. Cause-specific mortality 
after a breast cancer diagnosis: a cohort study of 10,195 women 
in Girona and Tarragona. Clin Transl Oncol 2019; published online 
Jan 3. DOI:10.1007/s12094-018-02015-5.
24 Boekel NB, Schaapveld M, Gietema JA, et al. Cardiovascular disease 
risk in a large, population-based cohort of breast cancer survivors. 
Int J Radiat Oncol Biol Phys 2016; 94: 1061–72.
25 UK Data Service Census Support. Deprivation data. 2019. 
https://census.ukdataservice.ac.uk/get-data/related/deprivation. 
(accessed Jan 10, 2018).
26 Riihimaki M, Thomsen H, Brandt A, Sundquist J, Hemminki K. 
Death causes in breast cancer patients. Ann Oncol 2012; 
23: 604–10.
27 Tweed EJ, Allardice GM, McLoone P, Morrison DS. Socio-economic 
inequalities in the incidence of four common cancers: 
a population-based registry study. Public Health 2018; 154: 1–10.
28 Brand JS, Hedayati E, Bhoo-Pathy N, et al. Time-dependent risk 
and predictors of venous thromboembolism in breast cancer 
patients: a population-based cohort study. Cancer 2017; 123: 468–75.
29 Cronin-Fenton DP, Søndergaard F, Pedersen LA, et al. 
Hospitalisation for venous thromboembolism in cancer patients 
and the general population: a population-based cohort study in 
Denmark, 1997–2006. Br J Cancer 2010; 103: 947–53.
30 Walker AJ, West J, Card TR, Crooks C, Kirwan CC, Grainge MJ. 
When are breast cancer patients at highest risk of venous 
thromboembolism? A cohort study using English health care data. 
Blood 2016; 127: 849–57.
31 Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. 
Validation and validity of diagnoses in the General Practice Research 
Database: a systematic review. Br J Clin Pharmacol 2010; 69: 4–14.
32 Herrett E, Shah AD, Boggon R, et al. Completeness and diagnostic 
validity of recording acute myocardial infarction events in primary 
care, hospital care, disease registry, and national mortality records: 
cohort study. BMJ 2013; 346: f2350.
33 Arhi CS, Bottle A, Burns EM, et al. Comparison of cancer diagnosis 
recording between the Clinical Practice Research Datalink, 
Cancer Registry and Hospital Episodes Statistics. Cancer Epidemiol 
2018; 57: 148–57.
34 White IR, Carlin JB. Bias and efficiency of multiple imputation 
compared with complete-case analysis for missing covariate values. 
Stat Med 2010; 29: 2920–31.
35 Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of 
anthracycline agents for the treatment of cancer: systematic review 
and meta-analysis of randomised controlled trials. BMC Cancer 
2010; 10: 337.
36 Bowles EJA, Wellman R, Feigelson HS, et al. Risk of heart failure 
in breast cancer patients after anthracycline and trastuzumab 
treatment: a retrospective cohort study. J Natl Cancer Inst 2012; 
104: 1293–305.
37 Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease 
in women after radiotherapy for breast cancer. N Engl J Med 2013; 
368: 987–98.
38 Lenneman CG, Sawyer DB. Cardio-oncology: an update on 
cardiotoxicity of cancer-related treatment. Circ Res 2016; 118: 1008–20.
39 Hippisley-Cox J, Coupland C, Brindle P. Development and 
validation of QRISK3 risk prediction algorithms to estimate future 
risk of cardiovascular disease: prospective cohort study. BMJ 2017; 
357: j2099.
40 Pareek N, Cevallos J, Moliner P, et al. Activity and outcomes of 
a cardio-oncology service in the United Kingdom—a five-year 
experience. Eur J Hear Fail 2018; 20: 1721–31.
41 Lancellotti P, Suter TM, Lo T, et al. Cardio-oncology services: 
rationale, organization, and implementation. Eur Heart J 2019; 
40: 1756–63.
42 Walter FM, Usher-Smith JA, Yadlapalli S, Watson E. Caring for 
people living with, and beyond, cancer: an online survey of GPs 
in England. Br J Gen Pract 2015; 65: e761–68.
43 Chidwick K, Strongman H, Matthews A, et al. Statin use in cancer 
survivors versus the general population: cohort study using primary 
care data from the UK Clinical Practice Research Datalink. 
BMC Cancer 2018; 18: 1018.
